J Immunother Cancer: Research by Prof. Xiaohua Wu's team of Fuzhu shows that camrelizumab combined with famitinib can be an effective treatment for platinum-resistant recurrent ovarian cancer

Recently, J Immunother Cancer published a research result from the team of Professor Wu Xiaohua of Fudan University Affiliated Cancer Hospital, mainly to evaluate the PD-1 inhibitor camrelizumab combined with famitinib in the treatment of platinum resistance.
Efficacy of drug-relapsed ovarian cancer
.

Recently, J Immunother Cancer published a research result from the team of Professor Wu Xiaohua of Fudan University Affiliated Cancer Hospital, mainly to evaluate the PD-1 inhibitor camrelizumab combined with famitinib in the treatment of platinum resistance.
Efficacy of drug-relapsed ovarian cancer
.

ovarian cancer

The study is an open-label, multicenter Phase II clinical study
.

Eligible patients with platinum-resistant ovarian cancer who received camrelizumab (200 mg intravenously every 3 weeks) and oral famitinib (20 mg once daily) were enrolled

The study is an open-label, multicenter Phase II clinical study

From April 19, 2019, to April 9, 2020, a total of 37 platinum-resistant patients received camrelizumab + famitinib

At the cutoff date of April 9, 2021, 9 (24.

Efficacy assessment

Efficacy assessment

Median follow-up was 22.
0 months (range, 12.
0 - 23.
7), median progression-free survival (PFS) was 4.
1 months (95% CI, 2.
1 - 5.
7), and median OS was 18.
9 months (95% CI) , 10.
8 - not reached)
.

The OS rates at 6, 9, and 12 months were 89.

Median follow-up was 22.

             PFS and OS

 PFS and OS

The ORRs for primary platinum-resistant, secondary platinum-resistant, and primary platinum-refractory patients were 36.
4% (95% CI, 10.
9-69.
2), 13.
3% (95% CI, 1.
7-40.
5) and 27.
3% (95% CI, 6.
0-61.
0)
.

The DCRs were 72.

The ORRs for primary platinum-resistant, secondary platinum-resistant, and primary platinum-refractory patients were 36.

The ORR for PD-L1 CPS ≥1 and <1 patients was 50.

The most common grade 3 treatment-related adverse events were hypertension (32.

                 Adverse reactions

Adverse reactions

In conclusion, the study showed that the combination of camrelizumab and famitinib showed antitumor activity in treated platinum-resistant patients with acceptable safety, which deserves further exploration
.

In conclusion, the study showed that the combination of camrelizumab and famitinib showed antitumor activity in treated platinum-resistant patients with acceptable safety, which deserves further exploration
.

Studies have shown that the combination of camrelizumab and famitinib showed antitumor activity in previously treated platinum-resistant patients with acceptable safety, which deserves further exploration

Original source:

Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, Zhang Y, Sun R, Zhou X, Wang Q, Wu X.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
J Immunother Cancer.
2022 Jan;10(1):e003831.
doi: 10.
1136/jitc-2021-003831.
PMID: 35017154.

Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, Zhang Y, Sun R, Zhou X, Wang Q, Wu X.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
J Immunother Cancer.
2022 Jan;10(1):e003831.
doi: 10.
1136/jitc-2021-003831.
PMID: 35017154.
Leave a message here